AI
DFTX

Allostery Investments’s Definium Therapeutics DFTX Stock Holding History

Allostery Investments’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-130,000
Closed -$905K – 48
2024
Q4 		$905K Buy
+130,000
New +$894K 0.95% 21

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Allostery Investments's DFTX Position: Q1 2025 in Review

Allostery Investments sold out of Definium Therapeutics (DFTX) in Q1 2025, closing a stake of 130,000 shares — an estimated $905K sold.

Allostery Investments first reported a position in DFTX in Q4 2024 and held it in 1 quarter. The position peaked at $905K in Q4 2024. 190 funds tracked by Wall St. Rank hold DFTX as of Q1 2025.

  • Allostery Investments reported no remaining Definium Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Allostery Investments sold 130,000 Definium Therapeutics shares in Q1 2025, an estimated $905K.
  • Allostery Investments first reported a position in Definium Therapeutics in Q4 2024 and held it in 1 quarter.
  • Allostery Investments's Definium Therapeutics position peaked at $905K in Q4 2024.
  • 190 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2025.

Based on Allostery Investments's 13F filing for Q1 2025, filed 15 May 2025.